In Swift Challenge To Orange Book Patent Listings, Federal Trade Commission Fills FDA Ministerial Gap
Executive Summary
Agency sends letters to 10 companies saying they improperly listed patents in US FDA’s Orange Book covering drug-device combination products. FTC does not specify why it believes the patents were improperly listed.
You may also be interested in...
Biosimilar Interchangeable Exclusivity Guidance Still Planned Despite Memo Release, US FDA Says
While many interpretations of the law protecting the first interchangeable biosimilar approved for a reference product are included in a recently released FDA memo, the agency says it has a limited scope.
Biosimilar Interchangeable Exclusivity Guidance Still Planned Despite Memo Release, US FDA Says
While many interpretations of the law protecting the first interchangeable biosimilar approved for a reference product are included in a recently released FDA memo, the agency says it has a limited scope.
FTC Campaign Against Orange Book Patent Listings Extends To Mylan’s Battle With Sanofi
Sanofi’s Orange Book listings for its insulin glargine product ‘can be viewed as one part of an overarching monopolistic scheme,’ FTC says in amicus brief.